My take on the crizotinib Xalkori FDA approval
Pfizer’s Crizotinib (Xalkori) approved in ALK-positive lung cancer!
The FDA just announced that they have approved Pfizer’s crizotinib (Xalkori):
The U.S. Food and Drug Administration today approved Xalkori (crizotinib) to treat certain patients with late-stage (locally advanced or metastatic), non-small cell lung cancers (NSCLC) who express the abnormal anaplastic lymphoma kinase (ALK) gene.
Xalkori is being approved with a companion diagnostic test that will help determine if a patient has the abnormal ALK gene, a first-of-a-kind genetic test called the Vysis ALK Break Apart FISH Probe Kit. It is the second such targeted therapy approved by the FDA this year.
